4.7 Article

Switching to Sulphonylureas in Children With iDEND Syndrome Caused by KCNJ11 Mutations Results in Improved Cerebellar Perfusion

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Radiology, Nuclear Medicine & Medical Imaging

EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2

Oezlem L. Kapucu et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2009)

Article Endocrinology & Metabolism

Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation

A. S. Slingerland et al.

DIABETIC MEDICINE (2008)

Article Endocrinology & Metabolism

The G53D mutation in Kir6.2 (KCNJ11) is associated with neonatal diabetes and motor dysfunction in adulthood that is improved with sulfonylurea therapy

Joseph C. Koster et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)

Article Clinical Neurology

Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11

Woj Ciech Mlynarski et al.

NATURE CLINICAL PRACTICE NEUROLOGY (2007)

Article Physiology

Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes

Christophe A. J. Girard et al.

PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2006)

Article Medicine, General & Internal

Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations

Ewan R. Pearson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2006)

Article Biochemistry & Molecular Biology

Functional effects of KCNJ11 mutations causing neonatal diabetes:: enhanced activation by MgATP

P Proks et al.

HUMAN MOLECULAR GENETICS (2005)